Home / The teams / Infectious diseases in lower-income countries – IDLIC

Infectious diseases in lower-income countries – IDLIC

Our team was created in 1994. We conduct clinical research, epidemiological and public health research, community-based research in humanitarian settings, as well as social sciences research. Our main research area has been HIV and associated diseases. We are now developing additional expertise in other infectious diseases (tuberculosis, viral hepatitis B and C, viral haemorrhagic fevers), as well as non-communicable diseases.
We are a multi-disciplinary team, composed mainly of clinicians, medical epidemiologists, biostatisticians, social scientists, IT specialists, clinical research assistants, and data managers. We have built a very strong relationship with the PAC-CI research program in Côte d’Ivoire (ANRS research site in Côte d’Ivoire), and have been jointly labelled “Laboratoire International Associé” by Inserm and University of Bordeaux. Part of our team is based in Abidjan. In Bordeaux, the team is currently composed of 21 researchers, 13 technicians/engineers and 12 doctoral/post-doctoral students.

Objectives

The overall objectives of our multidisciplinary research team are to provide clinical and epidemiological data, primarily on infectious diseases, at individual and population-level, and to conceive and evaluate innovative interventions aimed at improving health outcomes in low-income countries.

On-going research projetcs

(Alphabetical order)


Large research platforms/consortiums

  • CORAL – Clinical and Operational Research Alliance (2016-ongoing): Research platform aimed at developing high-quality innovative and transformative research programs in partnership with the humanitarian organization ALIMA (Alliance for International Medical Action), primarily on improvement of maternal and child health outcomes on the Sahelian region (Co-Leaders: Renaud Becquet & Augustin Augier)
  • IeDEA – International epidemiological Databases to Evaluate AIDS, West Africa (2006-2021): Collaborative platform gathering routine individual data in HIV adult and paediatric care services at 30 health facilities located all over west-Africa and leading to ancillary research projects – cross-sectional studies and longitudinal cohort studies (PI: François Dabis)
  • Mereva Clinical Trial Unit (2008-ongoing): Joint clinical trial platform between the IDLIC team in Bordeaux and the PACCI program in Abidjan, Côte d’Ivoire. Funded by the French agency for research on AIDS and viral hepatitis (ANRS), Mereva has been conducting game-changing clinical trials on HIV/AIDS, such as the Temprano trial, and is currently coordinating and monitoring several international trials in the field of HIV/AIDS and other associated diseases such as hepatitis or tuberculosis: ANRS 12290 Statis, ANRS 12294 FIT-2, ANRS 12300 RFELATE 2, ANRS 12311 TAC, TB-Speed, ANRS 12372 MODERATO (Co-Leaders: Xavier Anglaret, Raoul Moh & Olivier Marcy)

 

HIV treatment strategies and models of care

  • FIT-2 (ANRS 12294, 2016-2020): Phase II randomized controlled trial. Evaluation of three first-line ART regimens for treatment of HIV-2 infection (Co-PIs: Françoise Brun Vezinet & Serge Eholie)
  • TAC (ANRS 12311, 2015-2018): Pilot study. Interferon-free therapy of chronic hepatitis C with sofosbuvir plus weight-based ribavirin (SOF+RBV)(genotype 2) or sofosbuvir/ ledipasvir (GT1 or 4) (Co-PIs: Karine Lacombe & Alain Attia)
  • THILAO (ANRS 12269, 2014-2018): Pilot study. Efficacy of a third-line based including darunavir plus raltegravir in HIV-infected adults who failed a protease inhibitor-based second-line ART in sub-Saharan Africa (Co-PIs: Roland Landman & Serge Eholie)
  • INSPIRE (Department of Foreign Affairs, Trade and Development Canada & WHO, 2015-2019): Phase III cluster-randomized trials. Evaluation of various implementation strategies aiming at eliminating the risk of mother-to-child transmission of HIV in Nigeria, Zimbabwe and Malawi (Co-PIs: Joanna Orne-Gliemann & Renaud Becquet)
  • Treatment-as-Prevention – TasP (ANRS 12249, 2011-2018): Phase III Cluster-randomized trial. Impact of immediate ART on HIV incidence in rural South Africa (Co-PIs: François Dabis & Deenan Pillay)
  • TasP long-term follow-up (ANRS 12249, 2018-2020): Cohort study. Care status and virological outcomes among TasP patients (Co-PIs: Joanna Orne-Gliemann & Collins Iwuji)
  • WETIV-R (NIH, 2016-2021): Intervention cohort study. Integration of reproductive health services exclusively provided by midwifes into routine HIV care, in Abidjan, Côte d’Ivoire (Co-PI: Renaud Becquet & Albert Minga)
  • MODERATO (ANRS 12372, 2018-2022): Phase III randomized controlled Efficacy of a dual maintenance therapy strategy (DTG/3TC or ATV/r+3TC) in who have been on successful 1st line ART with TDF-XTC-EFV since more than 2 years (Co-PIs: Roland Landman & Serge Eholie)

 

HIV prevention and HIV testing

  • DOD-CI (ANRS 12323, 2015-2018): Social sciences survey. Demand for and availability of testing services for HIV and hepatitis B&C in Côte d’Ivoire (Co-PIs: Joseph Larmarange & Christine Danel)
  • PRINCESSE (ANRS 12381, 2018-2021): Cohort study. PrEP, STIs, contraception, hepatitis B virus, sexual health for female sex workers in Côte d’Ivoire (Co-PIs: Serge Eholié & Joseph Larmarange)
  • PrEP-CI (ANRS 12361, 2017-2018): Feasibility study. PrEP among HIV-exposed women in Côte d’Ivoire (Co-PIs: Serge Eholié & Joseph Larmarange)

 

Tuberculosis and tuberculosis/HIV co-infection

  • TB-Speed (Unitaid, 2017-2021): Clinical and operational research program study. Improving diagnosis of tuberculosis in children to reduce mortality (Co-PIs: Olivier Marcy & Eric Wobudeya & Maryline Bonnet)
  • Reflate (ANRS 12300, 2016-2019): Clinical trial. Testing an alternative antiretroviral regimen (raltegravir) in HIV-infected patients treated for tuberculosis. (Co-PIs: Beatriz Grinsztejn & Nathalie de Castro)
  • Statis (ANRS 12290, 2016-2018): Clinical trial. Empirical tuberculosis treatment in severely immuno-compromised HIV-infected patients (Co-PIs: Xavier Blanc & Serge Domoua)

 

Non-communicable diseases/long-term chronic conditions

  • Cancer epidemiology in West Africa (2016-2021): Observational studies exploring the association between infectious agents (HIV, viral hepatitis) and various cancers in West Africa (Project director: Antoine Jaquet)
  • Mental health (2016-2021): Observational and cohort studies. Neuropsychological complications of HIV in older patients, management of depression among patients living with HIV (Project director: Charlotte Bernard)
  • Multi-Morbidity (ANRS 12371, 2017-2018): Qualitative research. Management of multi-morbidity in rural South Africa (Co-PIs: Joanna Orne-Gliemann & Max Bachmann)

 

Maternal and child health community-based research in humanitarian settings

  • CPS+LNS study (2016-2018): Cluster-randomized trial. Effect of concurrent use of seasonal malaria chemoprevention (SMC) plus a lipid-based nutrient supplement (LNS) on the occurrence of malaria episodes compared to use of SMC alone among children in rural Mali (Co-PI: Renaud Becquet & Susan Shepherd)
  • 1,000 days study (2016-2019): Intervention cohort study. Comprehensive package of antenatal and post-partum care services to reduce infant mortality and prevent undernutrition in children in rural Niger (Co-PI: Renaud Becquet & Susan Shepherd)
  • OPTIMA – Optimizing Treatment of acute malnutrition (2017-2019): Intervention cohort study. Simplified model for treating severe and moderate forms of acute malnutrition in rural Burkina Faso (Co-PI: Renaud Becquet & Susan Shepherd)
  • Crypto project (2017-2019): Set of preparatory epidemiological studies. Infectious causes of diarrhoea in acutely malnourished children with a focus on Cryptosporidium infection in urban and rural Chad (Co-PI: Renaud Becquet & Susan Shepherd)
  • Tchandra project (2018-2020): Set of preparatory epidemiological and qualitative studies. Reproductive health and childbearing practices in rural Chad (Co-PI: Renaud Becquet & Susan Shepherd)

 

Maternal and child health, gestational malaria

  • SEPSIS (Biomérieux, 2015-2018): Cohort study. Neonatal immune function and risk of sepsis in premature infants in Benin (Co-PIs: Nadine Fievet, Pierre Tissières, Alexandra Pachot; Co-Investigator: Valérie Briand)
  • RECIPAL (ANR-Fondation de France-FIND, 2014-2019): Pre-conception cohort study. Impact of gestational malaria on foetal growth (PI: Valérie Briand)

 

Emerging & re-emerging infectious diseases

  • ALERRT – African coaLition for Epidemic Research, Response and Training (EDCTP, 2017-2021): Collaborative research program (21 partner organisations from 13 countries – 4 European and 9 African). Reduction of the public health and socio-economic impact of disease outbreaks in Sub Saharan Africa by building sustainable clinical and laboratory research preparedness and response network. Emerging & re-emerging infectious diseases (WP1 leader: Serge Eholie; WP1 Coordinator: Eric Ouattara; Consortium leader: Peter Horby)
  • Cohort study. Patients infected with Lassa Fever Virus in Nigeria (Co-PIs: Denis Malvy Oladele Ayodeji; Coordinator: Alexandre Duvignaud)
  • RIPOST – Réseau des Instituts Nationaux de Santé Publique d’Afrique de l’Ouest (AFD, 2017-2021) Strengthen technical and managerial skills in six west African states (Benin, Burkina Faso, Ivory Cost, Guinea, Niger and Togo), through a dual interstate system: 1) training – action of health professionals in field epidemiology (surveillance and information systems, epidemic investigations and response); 2) research – action to strengthen social and community mobilization for the prevention and control of epidemics. (ISPED Coordinator: Mathias ALTMANN; Consortium leader: Preventive Medical Agency)

 

Modelling infectious diseases and health economic impact

  • CEPAC international (NIH/NIAID, 2015-2018): Mathematic model to project health and economic outcomes and comparing testing, preventive and therapeutic interventions in HIV infected patients. (Consortium leaders: Kenneth Freedberg & Rochelle Walensky; French PI: Xavier Anglaret; Côte d’Ivoire PI: Eric Ouattara)
  • MoDeL-CI (ANRS 12378, 2017-2018): Exploratory study. Data needs for modelling HIV incidence at regional and districts in Côte d’Ivoire, and for optimizing HIV testing policies (Co-PI: Eric Ouattara & Joseph Laramarange)

 



Main publications

  1. Accrombessi M, Fievet N, Yovo E, Cottrell G, Agbota G, Massougbodji A, Cot M, Briand V. Prevalence and associated risk factors of malaria in the first trimester of pregnancy: a pre-conceptional cohort study in Benin. J Infect Dis. 2018 (in press).
  2. Iwuji C, Orne-Gliemann J, Larmarange J, et al. Universal Test and Treat and the HIV epidemic in rural South Africa; a community cluster randomized trial. Lancet HIV. 2018 Mar;5(3):e116-e125.
  3. Jaquet A, Tchounga B, Tanon A, Bagny A, Ekouevi DK, Traore HA, Sasco AJ, Maiga M, Dabis F. Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer. 2018 Mar 23. [ahead of print].
  4. Marcy O, Tejiokem M, Msellati P, Truong HK, Do CV, Tran ND, (…)  Blanche S, for the ANRS 12229 PAANTHER 01 Study Group. Mortality and its determinants in ART-naive HIV-infected children with a suspicion of tuberculosis, an observational cohort study. Lancet HIV. 2018;5(2):e87-e95.
  5. Arikawa S, Rollins N, Jourdain G, et al. Contribution of maternal ART and breastfeeding to 24-month survival in HIV-exposed uninfected children: an individual pooled analysis of African and Asian studies. Clin Infect Dis. doi: 10.1093/cid/cix1102
  6. Oyeledun B, Phillips A, Oronsaye F, Alo O, Shaffer N, Osibo B, (…)  Becquet R. The effect of a continuous quality improvement intervention on retention-in-care at 6 months postpartum of pregnant women and mothers in an HIV antiretroviral programme in Northern Nigeria: results of a cluster randomized controlled study. J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S156-S164.
  7. Foster G, Orne-Gliemann J, Font H, et al. The impact of facility-based mother support groups on retention in care and PMTCT outcomes in rural Zimbabwe: the EPAZ cluster-randomised controlled trial. J Acquir Immune Defic Syndr. 2017; 75(Suppl 2): S207-15.
  8. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, (…) Eholie SP, Anglaret X. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080‑9
  9. Sissoko D, Duraffour S, Kerber R, Kolie JS, Beavogui AH, Camara AM, (…) Malvy D, Carroll M, Anglaret X, Gunther S. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health. 2017;5(1):e80‑
  10. Marcy O, Ung V, Goyet S, et al. Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children. Clin Infect Dis. 2016; 62(9): 1161-8.
  11. Orne-Gliemann J, Zuma T, Chikovore J, et al. Community perceptions of repeat HIV-testing: experiences of the ANRS 12249 Treatment as Prevention trial in rural South Africa. AIDS Care. 2016; 28 Suppl 3: 14-23.
  12. Sissoko D, Laouenan C, Folkesson E, M’Lebing A-B, Beavogui A-H, (…) Anglaret X, Malvy D. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13(3):e1001967
  13. Ouattara EN, Robine M, Eholie SP, et al. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis 2016; 62(11): 1454-62.
  14. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, (…) Eholié SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373(9): 808-22.
  15. Jaquet A, Odutola M, Ekouevi DK, Tanon A, Oga E, Akakpo J, (…) Dabis F; IeDEA West Africa Collaboration. Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiol. 2015 Dec;39(6):1060-5.
  16. Rollins NC, Becquet R, Orne-Gliemann J, et al. Defining and analyzing retention-in-care among pregnant and breastfeeding HIV-infected women: unpacking the data to interpret and improve PMTCT outcomes. J Acquir Immune Defic Syndr. 2014; 67 Suppl 2: S150-6.

Details

Centre de recherche INSERM U1219
Université de Bordeaux – ISPED Case 11
146 rue Léo-Saignat
33076 BORDEAUX cedex

Tél : +33 (0)5 57 57 15 80
Tél : +33 (0)5 57 57 92 40
Tél : +33 (0)5 57 57 95 69

  • Director :
    Read more ›
  • Co-director :
    cropped-user_picto22.png

    Renaud Becquet

    Chargé de Recherche INSERM
    Responsable pédagogique du Master Santé Internationale

    Parcours

    2014       

    “Habilitation à diriger des recherches” in Public Health and Epidemiology 

    Institute of Public Health & Epidemiology, Bordeaux University , Bordeaux, France

    2002 – 2005           

    PhD in Public Health and Epidemiology

    Institute of Public Health & Epidemiology, University Victor Segalen, Bordeaux, France

    Fellow of the French Ministry of Education, Research and Technology

    2001 – 2002

    Master of Public Health, Biostatistics and Epidemiology 

    Institute of Public Health & Epidemiology, University Victor Segalen, Bordeaux, France

    2000 – 2001

    Post-graduate diploma in Public Health 

    Institute of Public Health & Epidemiology, University Victor Segalen, Bordeaux, France

    Read more ›
  • Contacts : Alexandra Doring – Elodie Vernoux – Gwenaëlle Clouet – Elodie Rabourdin


Informations

News

logo_ISPED logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_ARS logo_Charles-Perrens logo_IFSTTAR logo_HONcode